Xeris Biopharma Holdings, Inc. (XERS) Operating Income (Loss) USD 2020 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Xeris Biopharma Holdings, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2020 to 2024.
  • Xeris Biopharma Holdings, Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$14.2 M, a 7.29% decline year-over-year.
  • Xeris Biopharma Holdings, Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$45 M, a 32% increase year-over-year.
  • Xeris Biopharma Holdings, Inc. annual Operating Income (Loss) for 2023 was -$44 M, a 46.3% increase from 2022.
  • Xeris Biopharma Holdings, Inc. annual Operating Income (Loss) for 2022 was -$81.9 M, a 28.8% increase from 2021.
  • Xeris Biopharma Holdings, Inc. annual Operating Income (Loss) for 2021 was -$115 M, a 37.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$45 M -$14.2 M -$968 K -7.29% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$44 M -$9.84 M +$5.33 M +35.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 -$49.3 M -$4.91 M +$13.9 M +73.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 -$63.2 M -$16 M +$2.94 M +15.5% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 -$66.1 M -$13.3 M +$15.8 M +54.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$81.9 M -$15.2 M +$33.1 M +68.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 -$115 M -$18.8 M +$5.58 M +22.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$121 M -$18.9 M +$6.87 M +26.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$127 M -$29.1 M -$12.3 M -73.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$115 M -$48.3 M Oct 1, 2021 Dec 31, 2021 10-K 2024-03-06
Q3 2021 -$24.4 M -$10.6 M -77.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$25.8 M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 -$16.7 M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q3 2020 -$13.7 M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.